Search results
Your search for TFRC returned no results
Showing 151 to 200 of 2468 results for term
Showing 151 to 200 of 2468 results for term
uncertainties about the long-term clinical effectiveness of darvadstrocel compared with standard care. In particular, estimates of...
Question Long-term risk of renal scarring and impaired renal function: A well designed cohort study investigating...
Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)
Evidence-based recommendations on darvadstrocel (Alofisel) for previously treated complex perianal fistulas in adults with non-active or mildly active luminal Crohn’s disease.
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.
effective and cost effective in supporting return to work after recurrent short-term sickness absence in the UK? Any explanatory...
lived experience of older people with social care needs and multiple long-term conditions? Any explanatory notes(if applicable) Why this...
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.
Rehabilitation for chronic neurological disorders including acquired brain injury (NG252)
This guideline covers rehabilitation in all settings for children, young people and adults with a chronic neurological disorder, neurological impairment or disabling neurological symptoms due to acquired brain injury, acquired spinal cord injury, acquired peripheral nerve disorder, functional neurological disorder or progressive neurological disease.
Show all sections
Sections for NG252
- Overview
- Designing and commissioning rehabilitation services
- Assessing rehabilitation needs and goal setting
- Rehabilitation planning and delivery
- Information, advice and learning as part of rehabilitation
- Rehabilitation to maintain, improve or support function
- Rehabilitation to support education, work, social and leisure activities, relationships and sex
- Terms used in this guideline
Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)
Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)
Evidence-based recommendations on ivosidenib (Tibsovo) with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation.
This guideline covers the care of women with a singleton pregnancy at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women with a singleton pregnancy having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.
This guideline covers care before, during and after a planned knee, hip or shoulder replacement. It includes recommendations to ensure that people are given full information about their options for surgery, including anaesthesia. It offers advice for healthcare professionals on surgical procedures and ensuring safety during operations. It also offers guidance on providing support and rehabilitation before and after surgery.
Belimumab for treating active autoantibody-positive systemic lupus erythematosus (TA752)
Evidence-based recommendations on belimumab (Benlysta) for treating active autoantibody-positive systemic lupus erythematosus.
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
View recommendations for MPG1Show all sections
Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)
This quality standard covers recognition, early intervention and long-term management of bipolar disorder, psychosis and schizophrenia in children and young people (under 18). It also includes support for parents and carers. It describes high-quality care in priority areas for improvement.
View quality statements for QS102Show all sections
Sections for QS102
- Quality statements
- Quality statement 1: Assessment for a first episode of psychosis
- Quality statement 2: Family intervention
- Quality statement 3: Psychological intervention
- Quality statement 4: Support for carers
- Quality statement 5: Healthy lifestyle advice
- Quality statement 6: Monitoring for side effects of antipsychotic medication
- Quality statement 7 (developmental): Home treatment in crisis
Audit:- What is the clinical and cost effectiveness of collecting long-term outcomes in a national trauma audit system? Any explanatory...
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
Evidence-based recommendations on danicopan (Voydeya) with ravulizumab (Ultomiris) or eculizumab (Soliris) for paroxysmal nocturnal haemoglobinuria in adults with residual haemolytic anaemia.
Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.
ID NG65/2 Question Long-term complications of spondyloarthritis:- What is the incidence of long-term complications, in...
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
Question Long-term outcomes for children and young people displaying harmful sexual behaviour:- What are the long-term...
Question Short-term bridging treatment with glucocorticoids:- What is the clinical and cost effectiveness of short-term...
development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes. Any explanatory notes(if...
effectiveness of radiofrequency denervation for chronic low back pain in the long term? Any explanatory notes(if applicable) Why this is...
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.
Excess winter deaths and illness and the health risks associated with cold homes (NG6)
This guideline covers reducing the health risks (including preventable deaths) associated with living in a cold home. It aims to improve the health and wellbeing of people vulnerable to the cold. Improving the temperature in homes, by improving energy efficiency, may also help reduce unnecessary fuel consumption.
This quality standard covers referral and assessment for intermediate care and how to deliver the service. It covers bed-based intermediate care, crisis response, home-based intermediate care and reablement. It describes high-quality care in priority areas for improvement. It does not cover rehabilitation for specific conditions.
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive breast cancer that is locally advanced, inflammatory, or early-stage with a high risk of recurrence, in adults.
NG101/3 Question Breast reconstruction:- What are the long-term outcomes for breast reconstruction in women having radiotherapy to the...
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis (TA1057)
Evidence-based recommendations on relugolix–estradiol–norethisterone (Ryeqo) for treating symptoms of endometriosis in adults of reproductive age.
Show all sections
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
Recommendation ID CG71/2 Question What are the long-term effects of statin therapy on sub-clinical atherosclerosis in children with FH
Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type 4A in people of all ages.
This quality standard covers the care of women and their babies during labour and immediately after the birth. It covers women who go into labour at term, and includes women at low risk of complications during labour and those who go on to develop complications. It describes high-quality care in priority areas for improvement.
View quality statements for QS105Show all sections
Sections for QS105
- Quality statements
- Quality statement 1: Choosing birth setting
- Quality statement 2: One-to-one care
- Quality statement 3: Cardiotocography and initial assessment of a woman in labour
- Quality statement 4: Stopping cardiotocography
- Quality statement 5: Interventions during labour
- Quality statement 6: Delayed cord clamping
- Quality statement 7: Skin-to-skin contact
This quality standard covers renal replacement therapy services for adults with kidney failure. It includes treatment options, such as dialysis and kidney transplant. It describes high-quality care in priority areas for improvement.
View quality statements for QS72Show all sections
Sections for QS72
- Quality statements
- Quality statement 1: Education programmes
- Quality statement 2: Transplantation – pre-emptive
- Quality statement 3: Transplantation – on dialysis
- Quality statement 4: Dialysis access preparation
- Quality statement 5: Home-based dialysis
- Quality statement 6: Patient transport
- Quality statement 7: Transplantation – rapid access to a specialist histopathology service
Tofacitinib for treating active ankylosing spondylitis (TA920)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active ankylosing spondylitis.
This guideline covers complex rehabilitation needs after traumatic injury, including assessment and goal setting, rehabilitation plans and programmes, physical, psychological and cognitive rehabilitation, rehabilitation for specific injuries, coordination of rehabilitation in hospital, at discharge and in the community, and commissioning and organising rehabilitation services.
Upadacitinib for treating active ankylosing spondylitis (TA829)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)
This guideline sets out an antimicrobial prescribing strategy for managing and preventing acute exacerbations of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.
subsequent health assessments be carried out in prison for people serving long-term sentences? Any explanatory notes(if applicable) Why...
This quality standard covers the safe and effective use of medicines. It covers people of all ages who are taking medicines, including those who are not getting the full benefit from their medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS120Show all sections
Sections for QS120
- Quality statements
- Quality statement 1: Shared decision-making
- Quality statement 2: Patient involvement in reporting medicines-related patient safety incidents
- Quality statement 3: Learning from medicines-related patient safety incidents
- Quality statement 4: Medicines reconciliation in acute settings
- Quality statement 5: Medicines reconciliation in primary care
- Quality statement 6: Structured medication review
- About this quality standard
Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.
This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.
service and service user characteristics of highly specialist and longer-term high-dependency rehabilitation units that are associated...
Recommendation ID NG123/6 Question What is the long-term effectiveness of bladder wall injection with botulinum toxin type A for...
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing a pulmonary embolism (PE) or another deep vein thrombosis in adults.
symptom relief and functional ability in the short term and the need for further treatment in the longer term. Any...